Baxiva
Pre-clinicalWe are Baxiva, a biotechnology startup developing next-generation glycoconjugate vaccines to combat bacterial infections. Our mission is to address urgent global health needs by targeting pathogens with high clinical burden and rising antimicrobial resistance. Our lead program focuses on preventing urinary tract and invasive infections caused by Escherichia coli—the world’s leading cause of antibiotic-resistant infections.
About
We are Baxiva, a biotechnology startup developing next-generation glycoconjugate vaccines to combat bacterial infections. Our mission is to address urgent global health needs by targeting pathogens with high clinical burden and rising antimicrobial resistance. Our lead program focuses on preventing urinary tract and invasive infections caused by Escherichia coli—the world’s leading cause of antibiotic-resistant infections.
Funding History
1Total raised: $28M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile